*67% of patients with commercial insurance have 1st line coverage.1
*As evidenced by ARR, MRI (Gd+ T1 and T2 lesions), and 3- and 6-month CDP.2
Real patient who was compensated for time. Individual results may vary.
"I'm glad I started RMS treatment with KESIMPTA."
Walt: husband • dad • aeronautical engineer • taking KESIMPTA first line
MEET REAL RELAPSING MS PATIENTS
WHO ARE READY
FOR KESIMPTA
Real patient who was compensated for time. Individual results may vary.
ALONGSIDE™ KESIMPTA IS HERE TO SUPPORT YOUR PATIENTS
Leticia, Alongside Coordinator
80% OF ELIGIBLE PATIENTS WITH COMMERCIAL INSURANCE CAN START KESIMPTA IN 4 DAYS OR LESS THROUGH OUR BRIDGE PROGRAM4
Based on prescription data collected from April to September 2023.
YOUR ELIGIBLE, COMMERCIALLY INSURED PATIENTS PAY AS LITTLE AS A $0† COPAY
†Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance coverage for KESIMPTA may receive up to $18,000 in annual copay benefits. Patients with commercial insurance and an initial denial of coverage may receive up to 12 months of free product while coverage is pursued. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions at start.kesimpta.com.
ARR, annualized relapse rate; CDP, confirmed disability progression; DMT, disease-modifying therapy; Gd+, gadolinium-enhancing; MOA, mechanism of action; MRI, magnetic resonance imaging; MS, multiple sclerosis; RMS, relapsing multiple sclerosis; SC, subcutaneous.